Skip to main content
Log in

Understanding the Impact of Stimulants on Sleep in ADHD: Evidence from Systematic Assessment of Sleep in Adults

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Stimulants are widely prescribed to manage attention-deficit/hyperactivity disorder (ADHD) in adults. Stimulants promote wakefulness and can produce insomnia side effects. We hypothesized that systematic studies of sleep effects would reveal patterns of sleep impairment that may be important for clinicians to monitor and manage. We conducted a review and analysis of studies that measured sleep systematically during stimulant treatment in adults. We identified nine studies that met our search criteria, including four double-blind placebo-controlled studies. All studies recorded self-report subjective sleep quality data, three studies collected actigraphy data, and three studies collected polysomnography data. One study found better subjective sleep quality under open-label treatment conditions. Both polysomnography studies found improvement in aspects of sleep patterns. Two of the actigraphy studies suggested that adults receiving stimulant treatment may have less movement during sleep, and one showed reduction in amount of sleep. Further research could inform best practices for maintaining sleep quality during stimulant treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Surman C, et al. Managing sleep in adults with ADHD: from science to pragmatic approaches. Brain Sci. 2021;11(10):1361.

    Article  Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Association; 2013.

    Book  Google Scholar 

  3. Surman C, editor. ADHD in adults: a practical guide to evaluation and management. Springer; 2013.

    Google Scholar 

  4. Surman C, et al. Association between attention deficit/hyperactivity disorder and sleep impairment in adulthood: evidence from a large controlled study. J Clin Psychiatry. 2009;70(11):1523–9.

    Article  Google Scholar 

  5. Philipsen A. Sleep in adults with attention-deficit/hyperactivity disorder: a controlled polysomnographic study including spectral analysis of the sleep EEG. Sleep. 2005;28(7):877–84.

    Article  Google Scholar 

  6. Bijlenga D, et al. The role of the circadian system in the etiology and pathophysiology of ADHD: time to redefine ADHD? Atten Defic Hyperact Disord. 2019;11(1):5–19.

    Article  Google Scholar 

  7. Snitselaar MA, et al. Sleep and circadian rhythmicity in adult ADHD and the effect of stimulants: a review of the current literature. J Atten Disord. 2017;21(1):14–26.

    Article  Google Scholar 

  8. Adderall XRTM [package insert]. Wayne, Pennsylvania; Shire US Inc.; 2013.

  9. Vyvanse (lisdexamfetamine dimesylate) [package insert]. Lexington, MA; Shire US Inc.; 2017.

  10. Mydayis [package insert]. Lexington, MA; Shire US Inc.; 2017.

  11. Weiss MD, et al. Effect of a multi-layer, extended-release methylphenidate formulation (PRC-063) on sleep in adults with ADHD: a randomized, double-blind, forced-dose, placebo-controlled trial followed by a 6-month open-label extension. CNS Drugs. 2021;35:667–79.

    Article  CAS  Google Scholar 

  12. Adler LA, et al. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. J Clin Psychopharmacol. 2011;31(1):108–14.

    Article  CAS  Google Scholar 

  13. Schiffer WK, et al. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse. 2006;15(4):243–51.

    Article  Google Scholar 

  14. Schwartz MD, et al. The neurobiology of sleep and wakefulness. Psychiatr Clin N Am. 2015;38(4):615–44.

    Article  Google Scholar 

  15. Jones BE. Arousal and Sleep Circuits. Neuropsychopharmacology. 2020;45:6–20.

    Article  CAS  Google Scholar 

  16. Steriade M, et al. Brainstem control of wakefulness and sleep. New York: Plenum; 1990.

    Book  Google Scholar 

  17. Aston-Jones G, et al. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci. 1981;1:876–86.

    Article  CAS  Google Scholar 

  18. Wisor JP, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21(5):1787–94.

    Article  CAS  Google Scholar 

  19. Herrera-Solis A, et al. Dopaminergic modulation of sleep-wake states. CNS Neurol Disord Drug Targets. 2017;16(4):380–6.

    Article  CAS  Google Scholar 

  20. Andersen ML, et al. Electrophysiological correlates of sleep disturbance induced by acute and chronic administration of D-amphetamine. Brain Res. 2009;1249:162–72.

    Article  CAS  Google Scholar 

  21. Coogan AN, et al. Impact of adult attention deficit hyperactivity disorder and medication status on sleep/wake behavior and molecular circadian rhythms. Neuropsychopharmacology. 2019;44(1):1198–206.

    Article  CAS  Google Scholar 

  22. Sobanski E, et al. Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: A controlled polysomnographic study. Sleep. 2008;31:375–81.

    Article  Google Scholar 

  23. Adler LA, et al. Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. Behav Brain Funct. 2009;5:34.

    Article  Google Scholar 

  24. Kooij JJ, et al. The effect of stimulants on nocturnal motor activity and sleep quality in adults with ADHD: An open-label case-control study. J Clin Psychiatry. 2001;62:952–6.

    Article  CAS  Google Scholar 

  25. Boonstra AM, et al. Hyperactive night and day? Actigraphy studies in adult ADHD: a baseline comparison and the effect of methylphenidate. Sleep. 2007;30:433–42.

    Article  Google Scholar 

  26. Spencer TJ, et al. Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69:1766–75.

    Article  CAS  Google Scholar 

  27. Surman C, et al. Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials. J Clin Psychiatry. 2011;72:903–8.

    Article  Google Scholar 

  28. Goodman DW, et al. Randomized, 6-week, placebo-controlled study of treatment for adult attention-deficit/hyperactivity disorder: individualized dosing of osmotic-release oral system (OROS) methylphenidate with a goal of symptom remission. J Clin Psychiatry. 2017;78:105–14.

    Article  Google Scholar 

  29. Fredriksen M, et al. Impact of methylphenidate on sleep problems in adults with ADHD: a pilot polysomnography study. Nord J Psychiatry. 2021;75(3):234–8.

    Article  Google Scholar 

  30. Kessler RC, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163(4):716–23.

    Article  Google Scholar 

  31. Lunsford Avery JR, et al. Sleep disturbances in adolescents with ADHD: a systematic review and framework for future research. Clin Psychol Rev. 2016;50:159–74.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Craig B. H. Surman.

Ethics declarations

Funding

No sources of funding were used to assist with the preparation of this manuscript.

Conflicts of Interest

Dr. Craig Surman, MD, has received, in his lifetime, consulting fees from Eisai, McNeil, NLS Pharma, Nutricia, Pfizer, Adlon/Purdue, Rhodes, Shire, Somaxon, Sunovion, Supernus, Takeda, and Teva; payments for lectures from Alcobra, Arbor, McNeil, Janssen, Janssen-Ortho, Novartis, Shire, Reed/MGH Academy (funded by multiple companies), and GME CME (funded by multiple companies); royalties from Berkeley/Penguin for “FASTMINDS” How to Thrive if You have ADHD (or Think you Might)” and from Humana/Springer for ADHD in Adults: A Practical Guide to Evaluation and Management. Dr. Surman has also conducted clinical research at Massachusetts General Hospital supported by Abbot, Cephalon, Hilda and Preston Davis Foundation, Eli Lilly, Magceutics/Neurocentria, Jazz, Johnson & Johnson/McNeil, Lundbeck, Merck, Nordic Naturals, Shire, and Takeda. Daniel Walsh has no conflicts of interest that are directly relevant to the content of this article.

Availability of data and material

Not applicable.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Code availability

Not applicable.

Author contributions

CBHS: Direction of literature search and analysis of results, outline and draft of entire manuscript, editing and final revision of manuscript. DMW: Conduct of literature search, draft of methods and results sections, editing of manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Surman, C.B.H., Walsh, D.M. Understanding the Impact of Stimulants on Sleep in ADHD: Evidence from Systematic Assessment of Sleep in Adults. CNS Drugs 36, 253–260 (2022). https://doi.org/10.1007/s40263-022-00905-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-022-00905-5

Navigation